REG - Physiomics PLC - Senior Management Announcement

PhysiomicsAnnouncement

04/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241104:nRSD6203Ka&default-theme=true

RNS Number : 6203K  Physiomics PLC  04 November 2024

4 November 2024

 

Physiomics plc

("Physiomics" or the "Company")

 

Senior Management Announcement

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce the hiring this week
of a new senior member of its team, Dr Mark Davies, as Head of Quantitative
Pharmacology and Data Science.

 

Dr Mark Davies brings over 20 years' experience in drug development, both from
the perspective of working within major pharmaceutical companies (such as
AstraZeneca) as well as from within service businesses supporting biopharma
companies worldwide. During this time, his roles have spanned a variety of
different disease areas and phases of drug discovery and development. His main
areas of experience are within computational biology and data informatics
bringing a collaborative approach to improve how companies work with and
analyse datasets from different sources. He has numerous peer-reviewed
publications and broad experience in experimental techniques, informatics and
their applications to modelling, helping to answer critical questions in drug
discovery. More recently, he has worked in business development roles for
state-funded (Medicines Discovery Catapult) and multiple Contract Research
Organisations (service providers) across Europe, bringing a consultative
approach to the utility of informatics-based approaches to questions in the
healthtech and pharmaceutical industry. Mark has a PhD in Biological Sciences,
from the University of Warwick, UK, and B.Sc in Biochemistry from University
of Bath, UK.

 

This new senior role will be responsible for the Company's Modelling,
Simulation and Data Science service line and will work closely with the CEO
and Board on setting its overall strategic direction. Dr Davies' focus will be
to drive growth and operational excellence in this service area. He will work
closely with the Head of Business Development to expand our services and
market reach, helping to accelerate conversion of new opportunities into
contracts. From an operational standpoint, the role will provide operational
governance and line-management of the technical team, ensuring efficient
delivery of high-quality consultancy projects.

 

Dr Peter Sargent, CEO, commented: "We are delighted to welcome Mark to our
team. We feel that his unique mix of technical and commercial experience
spanning across modelling & simulation, data science and drug development,
he will be a great addition to the Company".

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFVALVLLIIS